• Exchange: NASDAQ CM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharmaceuticals

CYTR:US

3.6000 USD 0.0800 2.27%

As of 20:10:00 ET on 07/11/2014.

Snapshot for CytRx Corp (CYTR)

Open: 3.5000 Day's Range: 3.4600 - 3.7500 Volume: 1,020,546
Previous Close: 3.5200 52wk Range: 2.0000 - 8.3500 1-Yr Rtn: +40.08%

Stock Chart for CYTR

No chart data available.
  • CYTR:US 3.6000
  • 1D
  • 1M
  • 1Y
3.5200
Interactive CYTR Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for CYTR

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -1.0268
Est. EPS (USD) (12/2014) -0.5430
Est. PEG Ratio -
Market Cap (M USD) 200.80
Shares Outstanding (M) 55.78
30 Day Average Volume 2,041,458
Price/Book (mrq) 2.0534
Price/Sale (ttm) 369.8834
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/06/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for CYTR

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for CYTR

CytRx Corporation is a biopharmaceutical research and development company. The Company focuses in the development of high-value human therapeutics, specializing in oncology. CytRx is also developing two drug candidates based on its molecular chaperone regulation technology.

Steven A KriegsmanPresident/CEOJean-Yves Caloz "John"CFO/Treasurer
Benjamin S LevinSenior VP/Gen Counsel/SecretaryScott WielandSenior VP:Drug Development
More Company Profile & Key Executives for CYTR

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil